Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Cardiomyopathy | Case report

Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report

Authors: Jun yi Wang, Yong mei Hu, Jian xiong Liu, Xiao jia Luo

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

Congestive heart failure is rarely observed in patients with acromegaly. Excessive growth hormone secretion and elevation of insulin-like growth factor 1 contribute to pathological changes in myocyte growth and structure, cardiac contractility, vascular function, and in later stage may progress to cardiac dysfunction. Early recognition of the condition is paramount, though the insidious progression of the disease commonly results in late diagnosis. Current standard regimens of pharmacological therapy, surgical treatment, radiotherapy are designed to normalize serum levels of both insulin-like growth factor 1 and growth hormone. In patients with late-stage heart failure due to acromegalic cardiomyopathy, cardiac resynchronization therapy might be a desirable treatment to help cardiac synchronization, improve symptoms, and eventually reduce hospital admissions together with mortality rates.

Case presentation

We describe a case of a 49-year-old man with a history of acromegaly who presented to our hospital with a diagnosis of decompensated systolic heart failure. Serial electrocardiograms showed wide (160–200 ms) QRS duration with left bundle branch block. Echocardiography showed severe left ventricular dysfunction that simultaneously achieved a left ventricular ejection fraction of 16%. Surgical indication was rarely assessed by neurosurgeons. Given that the stereotactic radiosurgery together with pharmacotherapy produced infinitesimal effects, cardiac resynchronization therapy was performed. Owing to biventricular synchronization and holding back reverse remodeling, the patient’s symptoms were successfully alleviated, and he was discharged from the hospital.

Conclusions

Congestive heart failure is a rare complication in acromegaly-induced cardiomyopathy (occurs in only 3% of patients). Early diagnosis and treatment with curative drugs more than cardiovascular implantable electronic devices might lead to better surgical outcomes in this group of patients.
Literature
2.
go back to reference Vitale G, Pivonello R, Galderisi M, et al. Cardiovascular complications in acromegaly: methods of assessment. Pituitary. 2001;4:251–7.CrossRefPubMed Vitale G, Pivonello R, Galderisi M, et al. Cardiovascular complications in acromegaly: methods of assessment. Pituitary. 2001;4:251–7.CrossRefPubMed
3.
go back to reference Saccà L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol. 2003;59(6):660–71.CrossRef Saccà L, Napoli R, Cittadini A. Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol. 2003;59(6):660–71.CrossRef
4.
go back to reference Matta MP, Caron P. Acromegalic cardiomyopathy: a review of the literature. Pituitary. 2003;6(4)):203–7.CrossRefPubMed Matta MP, Caron P. Acromegalic cardiomyopathy: a review of the literature. Pituitary. 2003;6(4)):203–7.CrossRefPubMed
5.
go back to reference Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712–8.CrossRefPubMed Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712–8.CrossRefPubMed
6.
go back to reference Vitale G, Pivonello R, Lombardi G, Colao A. Cardiac abnormalities in acromegaly: pathophysiology and implications for management. Treat Endocrinol. 2004;3:309–18.CrossRefPubMed Vitale G, Pivonello R, Lombardi G, Colao A. Cardiac abnormalities in acromegaly: pathophysiology and implications for management. Treat Endocrinol. 2004;3:309–18.CrossRefPubMed
7.
go back to reference Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefPubMed Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefPubMed
8.
go back to reference Nazari N, Keykhavani A, Sayah S, Hekmat M, Golabchi A, Rad MA, Alizadeh A, Heidarali M. Role of electrophysiological study in patients with syncope and bundle branch block. J Res Med Sci. 2014;19(10):961–4.PubMedPubMedCentral Nazari N, Keykhavani A, Sayah S, Hekmat M, Golabchi A, Rad MA, Alizadeh A, Heidarali M. Role of electrophysiological study in patients with syncope and bundle branch block. J Res Med Sci. 2014;19(10):961–4.PubMedPubMedCentral
9.
go back to reference Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European society of cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Eur Heart J. 2013;34:2281–329.CrossRefPubMed Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European society of cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Eur Heart J. 2013;34:2281–329.CrossRefPubMed
10.
go back to reference Butt RP, Laurent GJ, Bishop JE. Collagen deposition and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol. 1995;68:330–5.PubMed Butt RP, Laurent GJ, Bishop JE. Collagen deposition and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur J Cell Biol. 1995;68:330–5.PubMed
11.
go back to reference Brüel A, Oxlund H. Biosynthetic growth hormone increase the collagen deposition rate in rat aorta and heart. Eur J Endocrinol. 1995;132:195–9.CrossRefPubMed Brüel A, Oxlund H. Biosynthetic growth hormone increase the collagen deposition rate in rat aorta and heart. Eur J Endocrinol. 1995;132:195–9.CrossRefPubMed
12.
go back to reference Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–44.CrossRefPubMed Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–44.CrossRefPubMed
13.
go back to reference Johnsen SP, Hundborg HH, Sørensen HT, Orskov H, Tjønneland A, Overvad K, Jørgensen JO. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005;90:5937–41.CrossRefPubMed Johnsen SP, Hundborg HH, Sørensen HT, Orskov H, Tjønneland A, Overvad K, Jørgensen JO. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005;90:5937–41.CrossRefPubMed
14.
go back to reference Vasan RS, Sullivan LM, D’Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2004;139:642–8.CrossRef Vasan RS, Sullivan LM, D’Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2004;139:642–8.CrossRef
15.
go back to reference Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13:51–6.CrossRefPubMed Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13:51–6.CrossRefPubMed
16.
go back to reference Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. J Clin Endocrinol Metab. 2003;88:3196–201.CrossRefPubMed Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. J Clin Endocrinol Metab. 2003;88:3196–201.CrossRefPubMed
17.
go back to reference Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89:71–5.CrossRefPubMed Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89:71–5.CrossRefPubMed
18.
20.
go back to reference Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175:181–90.CrossRefPubMed Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175:181–90.CrossRefPubMed
21.
go back to reference Shimakura A, Miyakoshi H, Ohkuwa H, Kitabayashi M, Komai T, Hisada A, Aoki K, Sakagami S, Kobayashi K, Takata S. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure. Jpn Heart J. 2002;43(1):69–77.CrossRefPubMed Shimakura A, Miyakoshi H, Ohkuwa H, Kitabayashi M, Komai T, Hisada A, Aoki K, Sakagami S, Kobayashi K, Takata S. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure. Jpn Heart J. 2002;43(1):69–77.CrossRefPubMed
22.
go back to reference Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004;151(Suppl 1):S93–101.CrossRefPubMed Colao A, Vitale G, Pivonello R, Ciccarelli A, Di Somma C, Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004;151(Suppl 1):S93–101.CrossRefPubMed
23.
go back to reference Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004;89:5308–13.CrossRefPubMed Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004;89:5308–13.CrossRefPubMed
24.
go back to reference MacCarthy P, Kearney M, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ. 2003;327:78–9.CrossRefPubMedCentralPubMed MacCarthy P, Kearney M, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ. 2003;327:78–9.CrossRefPubMedCentralPubMed
25.
go back to reference Thomas J, Dattani A, Zemrak F, et al. Renin-angiotensin system blockade improves cardiac indices in acromegaly patients. Exp Clin Endocrinol Diabetes. 2017;125:365–7.CrossRefPubMedCentralPubMed Thomas J, Dattani A, Zemrak F, et al. Renin-angiotensin system blockade improves cardiac indices in acromegaly patients. Exp Clin Endocrinol Diabetes. 2017;125:365–7.CrossRefPubMedCentralPubMed
26.
go back to reference Schwarz ER, Jammula P, Gupta R, et al. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both? J Cardiovasc Pharmacol Ther. 2006;11:232–44.CrossRefPubMed Schwarz ER, Jammula P, Gupta R, et al. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both? J Cardiovasc Pharmacol Ther. 2006;11:232–44.CrossRefPubMed
27.
go back to reference Albat B, Leclercq F, Serre I, Fille A, Baldet P, Grolleau-Raoux R, Thevenet A. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J. 1993;14(11):1572–5.CrossRefPubMed Albat B, Leclercq F, Serre I, Fille A, Baldet P, Grolleau-Raoux R, Thevenet A. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J. 1993;14(11):1572–5.CrossRefPubMed
28.
go back to reference Barra S, Looi KL, Gajendragadkar PR. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace. 2016;18:1187–93.CrossRefPubMed Barra S, Looi KL, Gajendragadkar PR. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace. 2016;18:1187–93.CrossRefPubMed
29.
go back to reference Ogano M, Iwasaki YK, Tanabe J, Takagi H, Umemoto T, Hayashi M, Miyauchi Y, Shimizu W. Cardiac resynchronization therapy restored ventricular septal myocardial perfusion and enhanced ventricular remodeling in patients with nonischemic cardiomyopathy presenting with left bundle branch block. Heart Rhythm. 2014;11(5):836–41.CrossRefPubMed Ogano M, Iwasaki YK, Tanabe J, Takagi H, Umemoto T, Hayashi M, Miyauchi Y, Shimizu W. Cardiac resynchronization therapy restored ventricular septal myocardial perfusion and enhanced ventricular remodeling in patients with nonischemic cardiomyopathy presenting with left bundle branch block. Heart Rhythm. 2014;11(5):836–41.CrossRefPubMed
Metadata
Title
Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report
Authors
Jun yi Wang
Yong mei Hu
Jian xiong Liu
Xiao jia Luo
Publication date
01-12-2019

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue